Biogen shares soar on Alzheimer's drug developments
A study found that Biogen's Alzheimer's drug lecanemab reduced cognitive and functional decline by 27% compared to a placebo over an 18-month period.
Full ArticleBiogen shares soar on Alzheimer's drug developments
FOXNews.com
0 shares
1 views
- More about:
Lecanemab- Biogen
- Alzheimer's disease
You might like
Related news coverage
Alzheimer's drug shows promise in early results of study
New Zealand Herald
Shares of Biogen and other drugmakers researching Alzheimer's disease soared after Japan's Eisai Co said its potential treatment..